ArticleFrontiers in microbiology2026
Polysaccharides from Er Chen Decoction: gastrointestinal fate, gut microbiota modulation and metabolomics.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Er Chen Decoction (ECD), a classical formula for phlegm-related disorders, contains polysaccharides (PECD) as an important bioactive fraction. This study systematically assessed their gastrointestinal absorption, digestive stability, fecal fermentation, and correlations with gut microbiota and metabolic changes. Methods: Results: No appreciable systemic absorption of FITC-labeled PECD was detected following gastrointestinal administration. During simulated digestion, the total sugar and reducing sugar contents, molecular weight distribution, monosaccharide composition, and infrared spectral profiles of PECD showed no significant changes, suggesting that its major polysaccharides were largely resistant to upper gastrointestinal digestion. During Conclusion: PECD exhibited limited absorption, resistance to upper gastrointestinal digestion, susceptibility to fecal microbial fermentation, which altered microbial composition, SCFAs, and metabolic profiles, supporting its further study as a candidate bioactive polysaccharide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.